TOP HEADLINES

Featured Story

Leaping Soliris sales send Alexion's bottom line soaring

Alexion has had a win-some, lose-some year, what with a pricing challenge in the U.K. and a series of recalls for its only marketed drug. But that drug, Soliris, just keeps on surging. Sales grew 39% for the third quarter, hitting $555 million, and profits amounted to $177 million of that.

Medicines Company sues lawyers for busting Angiomax patent filing deadline

The Angiomax patent saga has a new chapter. Medicines Co. has now sued its law firms, Ropes & Gray and Fish & Neave, saying lawyers busted deadline for a key patent filing, risking premature generic competition for its best-selling anticoagulant.

U.K. watchdogs back Bayer's Xarelto for heart attack patients

Bayer's Xarelto, which has been cruising along since it joined a new class of warfarin replacement therapies on the market, has faced a rare stumbling block in acute coronary syndrome--an indication the FDA has denied it on three separate occasions. But across the pond, it's picked up a nod in some ACS patients from the U.K.'s cost-effectiveness gatekeeper.

J&J Innovation taps Texas for its latest biotech startup incubator

Johnson & Johnson taking its network of biopharma incubators to Texas in an expansion of its Janssen Labs initiative.

Cancer survivor's petition pleads with Roche for lower Kadcyla price

Drugmakers are accustomed to grappling with government payers and PBMs over prices. They're used to getting the stiff arm from cost-effectiveness watchdogs like those at the U.K.'s National Institute for Health and Care Excellence (NICE). They're even used to the critics at patient-access organizations. But a pricing fight directly with patients? That's not your everyday occurrence.

MORE NEWS

From Our Sister Sites

FierceBiotech

In this week's EuroBiotech Report, Google revealed further details of its $100 million (€79 million) European venture capital unit, which is hunting for biotechs and startups in other sectors from its digs in London. And more.

FierceDiagnostics

As concern mounts over the deadly Ebola epidemic, French scientists are developing a diagnostic tool that works similar to a home pregnancy test and can quickly identify the virus through a tiny fluid sample.